XML 18 R9.htm IDEA: XBRL DOCUMENT
v3.22.2

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION | 6 Months Ended
--- | ---
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION | SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Supplemental Balance Sheet Information Inventory consisted of the following:
| June 30, 2022 |  | December 31, 2021
Raw materials | $ | 104,493 |  |  | $ | 80,269 |
Work-in-process | 429,486 |  |  | 415,261 |
Finished goods | 268,336 |  |  | 281,139 |
Total inventory | $ | 802,315 |  |  | $ | 776,669 |
Inventory as of June 30, 2022, included manufacturing-related costs for the commercial production of valoctocogene roxaparvovec totaling $31.8 million. Valoctocogene roxaparvovec is an investigational gene therapy product candidate for the treatment of severe hemophilia A. The Company must receive marketing approval from the applicable regulators before the valoctocogene roxaparvovec inventory can be sold commercially. Starting in the first quarter of 2022, the Company believed that material uncertainties related to the ultimate regulatory approval of valoctocogene roxaparvovec by the European Medicines Agency had been significantly reduced and the Company expects to realize economic benefit in the future. A number of factors were taken into consideration, including the current status in the drug development process, pivotal clinical trial results for the underlying product candidate, results from meetings and correspondence with the relevant regulatory authority following the submission of the additional two-year follow-up safety and efficacy data requested by the regulatory authority in the third quarter of 2020, historical experience, as well as potential impediments to the approval process such as product safety or efficacy, and commercialization and marketplace trends. See Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 for additional information related to the Company’s policies on inventory produced prior to regulatory approval. Property, Plant and Equipment, Net consisted of the following:
| June 30, 2022 |  | December 31, 2021
Property, plant and equipment, gross | $ | 1,811,263 |  |  | $ | 1,756,035 |
Accumulated depreciation | (761,799) |  |  | (720,574) |
Total property, plant and equipment, net | $ | 1,049,464 |  |  | $ | 1,035,461 |
Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2022 was $9.5 million and $21.2 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and six months ended June 30, 2021 was $11.8 million and $24.3 million, respectively. Intangible Assets, Net consisted of the following:
| June 30, 2022 |  | December 31, 2021
Finite-lived intangible assets | $ | 689,499 |  |  | $ | 677,350 |
Accumulated amortization | (320,131) |  |  | (288,698) |
Net carrying value | $ | 369,368 |  |  | $ | 388,652 |
Accounts Payable and Accrued Liabilities consisted of the following:
| June 30, 2022 |  | December 31, 2021
Accounts payable and accrued operating expenses | $ | 199,251 |  |  | $ | 193,003 |
Accrued compensation expense | 127,929 |  |  | 204,446 |
Accrued rebates payable | 62,485 |  |  | 47,987 |
Accrued royalties payable | 15,620 |  |  | 15,215 |
Foreign currency exchange forward contracts | 10,224 |  |  | 6,263 |
Lease liabilities | 10,611 |  |  | 10,464 |
Value added taxes payable | 2,472 |  |  | 1,935 |
Accrued income taxes | 1,568 |  |  | 1,213 |
Deferred revenue | 305 |  |  | 6,956 |
Other | 4,308 |  |  | 4,108 |
Total accounts payable and accrued liabilities | $ | 434,773 |  |  | $ | 491,590 |
Supplemental Statement of Comprehensive Income Information Gain on Sale of Nonfinancial Assets, Net for the six months ended June 30, 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of Voxzogo. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the Company's Consolidated Statement of Comprehensive Income.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration